MedTrace Logo

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

NCT00378482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-08-22

Study results available
· View outcomes & findings →

Summary

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.

Conditions

Interventions

DRUG

CP-675,206 (Tremelimumab)

15 mg/kg IV every 3 months as long as required

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca AstraZeneca · AstraZeneca

  • Peter Langmuir, Dir.Medic.Science · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-05
Primary Completion
2023-10-27
Completion
2023-10-27

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378482 on ClinicalTrials.gov